PNTV
Analyst Coverage
Cannabis Investor News in-house rating · cin-analyst-v1.0
Players Network carries an Underweight rating, with a 27.4 composite placing the shares firmly in the lowest rating band and conviction at 2/5. Regulatory is the strongest pillar at 49, driven by an 80 enforcement subscore, a 50 jurisdiction posture, and a weaker 25 cadence contribution. Market contributes 40 despite no quote being available from institutional pricing feeds, limiting price-based confirmation. Editorial contributes 30, reflecting no newsroom or brief activity in CIN newsroom coverage. Fundamentals contribute only 2, overwhelmingly defining the negative rating through failed growth, profitability, and capitalization measures.
Licensed fundamentals data show year-over-year revenue contracting by 78.2%, eliminating any operating-growth support for the equity case. Gross margin stands near negative 177%, while operating margin approaches negative 1,475%, indicating severe cost absorption and a business model operating far below economic scale. EBITDA is negative by roughly $3.8 million, and the cash-burn ratio is about 0.80, consistent with the stated stretched financial condition. The approximately $4.7 million market capitalization receives no tier credit, while cash runway supplies the fundamentals pillar’s only meaningful subscore at 15. Primary regulatory filings provide no latest filing date, and the record contains no regulatory events during either the trailing 90-day or 180-day periods. No enforcement hits support the regulatory pillar, but filing cadence remains deficient.
The clearest forward catalyst sits within regulatory, the highest-scoring pillar. A return to consistent primary regulatory filings would raise transparency around operations, capital structure, and financial continuity while directly addressing the weak cadence subscore. The favorable enforcement contribution and baseline jurisdiction posture already provide the strongest available support, but neither offsets collapsing revenue, deeply negative margins, negative EBITDA, absent institutional pricing, and limited CIN newsroom coverage. Regulatory progress therefore represents the most direct route to improved conviction, whereas continued silence reinforces the Underweight assessment and the stretched financial profile. The single most important signal to watch will be the appearance of a current primary regulatory filing that re-establishes a dependable reporting cadence.
- IR / PR agency
- 1-800-PublicRelations (1800pr)
- IR email
- ir@playersnetwork.com
- IR page
- Investor relations
- CEO
- Mark Bradley
- Website
- Company website
- Market cap
- $4.7M
- Price to sales
- 15.81
- Revenue (TTM)
- $267K
- Gross profit (TTM)
- $-473K
- EBITDA
- $-3.8M
- Operating margin
- -1474.7%
- Profit margin
- 0.0%
- Rev growth YoY
- -78.2%
- Return on equity
- 0.0%
- Return on assets
- -149.1%
- EPS (TTM)
- $-0.02
- Shares outstanding
- 678.1M
- Insider ownership
- 3.6%
- Institutional ownership
- 0.4%
- Beta
- -0.46
- Full-time employees
- 2
- GICS sector
- Healthcare
- GICS industry
- Drug Manufacturers - Specialty & Generic
- Filing portal
- SEC EDGAR
Help us keep coverage accurate. Submit an update for CIN editorial review.
Bullish and Bearish Analyst Opinions for PNTV (PNTV)
Cannabis Investor News aggregates analyst coverage, price targets, insider transactions, SEC filings, and financing activity for PNTV (PNTV), a cannabis-sector equity listed on OTCMKTS. Use this profile to compare bullish and bearish opinions, monitor Form 4 insider buys and sells, and review the latest quarterly results.
CIN editorial stance: Event-Driven Opportunity. Setup improving. Long-term outperformer detected. (2 bullish signals, 0 bearish signals.)
Historical Price Data
5-year weekly price history, intraday quotes, and 52-week range for PNTV are maintained by Cannabis Investor News and refreshed throughout the trading day.